Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

August 17, 2016 7:03 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities

Morgan Stanley, Options

Add Your Comment